KALA BIO (NASDAQ:KALA) Stock Price Down 0.8%

KALA BIO, Inc. (NASDAQ:KALA)’s stock price fell 0.8% during mid-day trading on Monday . The stock traded as low as $5.81 and last traded at $5.95. 8,097 shares changed hands during trading, a decline of 92% from the average session volume of 101,337 shares. The stock had previously closed at $6.00.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of KALA BIO in a research note on Monday, August 19th. HC Wainwright decreased their target price on shares of KALA BIO from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, May 17th.

KALA BIO Trading Up 1.7 %

The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.07 and a current ratio of 3.07. The company has a market capitalization of $27.71 million, a PE ratio of -0.40 and a beta of -2.12. The stock has a fifty day moving average of $6.43 and a 200 day moving average of $6.73.

KALA BIO (NASDAQ:KALA) last released its earnings results on Tuesday, August 6th. The company reported ($3.16) EPS for the quarter, topping the consensus estimate of ($4.40) by $1.24. As a group, sell-side analysts predict that KALA BIO, Inc. will post -11.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Mark T. Iwicki sold 15,168 shares of KALA BIO stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total value of $72,048.00. Following the sale, the chief executive officer now directly owns 263,755 shares of the company’s stock, valued at $1,252,836.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 23,984 shares of company stock worth $113,924 in the last 90 days. 13.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th largest holding. SR One Capital Management LP owned 15.76% of KALA BIO at the end of the most recent quarter. 24.61% of the stock is owned by institutional investors.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.